Details for Patent: 12,053,502
✉ Email this page to a colleague
Which drugs does patent 12,053,502 protect, and when does it expire?
Patent 12,053,502 protects DAPTOMYCIN and is included in one NDA.
This patent has eleven patent family members in nine countries.
Drugs Protected by US Patent 12,053,502
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xellia Pharms Aps | DAPTOMYCIN | daptomycin | POWDER;INTRAVENOUS | 217415-001 | Jan 30, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOOD STREAM INFECTIONS | ⤷ Sign Up | ||||
| Xellia Pharms Aps | DAPTOMYCIN | daptomycin | POWDER;INTRAVENOUS | 217415-002 | Jan 30, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOOD STREAM INFECTIONS | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,053,502
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018322769 | ⤷ Sign Up | |||
| Brazil | 112020003862 | ⤷ Sign Up | |||
| Canada | 3070660 | ⤷ Sign Up | |||
| China | 111093625 | ⤷ Sign Up | |||
| European Patent Office | 3675815 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
